Skip to content
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
BioTechGrid BioTechGrid
  • Home
  • Biotechnology
  • Medical Technology
  • Research
  • Genetics
  • Press Releases
    • Business Wire
    • GlobeNewswire
    • PRNewswire
  • Contact
  • Home
  • Biotechnology
  • MapLight dims preclinical programs to make phase 3-ready schizophrenia drug shine brighter

MapLight dims preclinical programs to make phase 3-ready schizophrenia drug shine brighter

August 14, 2026Posted inBiotechnology

Despite mixed results for its experimental schizophrenia treatment last month, MapLight Therapeutics is going all-in on the asset—at the expense of its preclinical programs.

Post navigation

Previous Post
levidex-rct-shows-clinically-significant-quality-of-life-improvements-in-multiple-sclerosis Levidex RCT Shows Clinically Significant Quality-of-Life Improvements in Multiple Sclerosis
Next Post
Cell Membrane Protein Quality Control Begins at the Ribosome cell-membrane-protein-quality-control-begins-at-the-ribosome

Recent Posts

  • FWB-SMOTE Algorithm Outperforms Eleven Benchmarks on Imbalanced Datasets Across Three Classifiers
  • Explainable Deep Learning Model Accurately Detects Industrial Network Cyber Threats
  • Smoothing Methods Enhance Machine Learning State-of-Health Predictions for Lithium-Ion Batteries
  • Forest Conditions Outside National Parks Strongly Influence Bird Presence Within Them
  • Maternal Poor Sleep Quality Linked to Congenital Heart Defects in Offspring

Archives

  • November 2026
  • October 2026
  • September 2026
  • August 2026
  • July 2026
  • September 2024
  • August 2024
  • March 2024
  • September 2023

Privacy Policy    Terms

Scroll to Top